Valuation: VolitionRx Limited

Market Cap 10.83M 9.46M 8.75M 8.08M 15.22M 1.04B 15.5M 104M 40.93M 509M 40.68M 39.78M 1.75B P/E 2026 *
-0.58x
P/E 2027 * -0.94x
Enterprise Value 10.83M 9.46M 8.75M 8.08M 15.22M 1.04B 15.5M 104M 40.93M 509M 40.68M 39.78M 1.75B EV / Sales 2026 *
4.37x
EV / Sales 2027 * 1.89x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-1.92%
1 week-9.19%
Current month-5.83%
1 month-11.72%
3 months-60.30%
6 months-78.89%
Current year-75.13%
1 week 1.24
Extreme 1.24
1.53
1 month 1.17
Extreme 1.17
1.56
Current year 1.17
Extreme 1.17
7.73
1 year 1.17
Extreme 1.17
16
3 years 1.17
Extreme 1.17
31
5 years 1.17
Extreme 1.17
82.8
10 years 1.17
Extreme 1.17
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Director/Board Member 55 05/10/2011
Director/Board Member 77 05/10/2011
Director/Board Member 64 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
03-16
Concord International, Inc.
OtherCompany 0 0%
03-16Tax

Company Secretary

3,948 0.0029%
03-16Tax

Executive/Senior Manager

5,251 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-1.92%-9.19%-90.72%-95.43% 10.83M
-1.69%+1.42%+113.73%+97.71% 4.59B
+1.38%+2.62%+84.98%+197.98% 3.36B
-1.34%-0.19%-27.21%-39.41% 2.07B
-0.87%-7.93%+99.26%-48.39% 1.8B
-0.05%+2.54%+45.00%+197.13% 1.49B
+3.22%+9.38%+142.51%-49.37% 938M
-2.81%-4.82%-14.26%+32.61% 868M
-5.41%-2.49%-5.84% - 501M
+2.71%-3.48%-36.58%-17.45% 471M
Average -0.69%+0.50%+31.09%+30.60% 1.61B
Weighted average by Cap. -0.54%-0.03%+68.15%+77.62%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 2M 1.85M 3.48M 238M 3.55M 23.87M 9.37M 117M 9.31M 9.1M 401M 5.73M 5.01M 4.63M 4.28M 8.06M 551M 8.2M 55.24M 21.67M 270M 21.54M 21.06M 929M
Net income -22.2M -19.4M -17.94M -16.57M -31.21M -2.13B -31.77M -214M -83.92M -1.04B -83.4M -81.56M -3.6B -19.62M -17.15M -15.85M -14.64M -27.58M -1.88B -28.07M -189M -74.16M -923M -73.69M -72.06M -3.18B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
14/07/26 US$1.275 -1.92% 111,132
13/07/26 US$1.300 -3.70% 130,769
10/07/26 US$1.350 +0.75% 395,279
09/07/26 US$1.340 -0.37% 157,796
08/07/26 US$1.345 -3.93% 225,175
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.300USD
Average target price
16.97USD
Spread / Average Target
+1,205.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock